Literature DB >> 2971602

Alzheimer's disease and Down's syndrome.

D M Mann1.   

Abstract

The neuropathology of Down's syndrome at middle age is compared with that of Alzheimer's disease at that age, through a review of the published literature and from the author's personal observations. The pathological changes of Down's syndrome at middle age, i.e. the form and distribution of senile plaques and neurofibrillary tangles, and the pattern of involvement (atrophy) of neuronal systems are qualitatively the same as those of Alzheimer's disease at that age. Quantitative differences do occur and these may relate to biological or sociological variations inherent to the two parent populations. It is concluded that, in pathological terms, patients with Down's syndrome at middle age do indeed have Alzheimer's disease. Some ways in which a study of patients with Down's syndrome can give insight into the nature and development of the pathological changes of Alzheimer's disease are put forward and discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971602     DOI: 10.1111/j.1365-2559.1988.tb02018.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  67 in total

1.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

2.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

Review 3.  Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors:  J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal:  J Autism Dev Disord       Date:  2007-01-13

Review 4.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 5.  Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.

Authors:  Todd E Golde
Journal:  Neuron       Date:  2019-03-20       Impact factor: 17.173

6.  Behaviour changes in an adult with Down syndrome.

Authors:  Cynthia J Forster-Gibson
Journal:  Can Fam Physician       Date:  2019-04       Impact factor: 3.275

Review 7.  What is strain in neurodegenerative diseases?

Authors:  Ye Tian; Lanxia Meng; Zhentao Zhang
Journal:  Cell Mol Life Sci       Date:  2019-09-17       Impact factor: 9.261

8.  Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice.

Authors:  Jessica A Ash; Ramon Velazquez; Christy M Kelley; Brian E Powers; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neurobiol Dis       Date:  2014-06-14       Impact factor: 5.996

Review 9.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Transchromosomic cell model of Down syndrome shows aberrant migration, adhesion and proteome response to extracellular matrix.

Authors:  Frédéric Delom; Emma Burt; Alex Hoischen; Joris Veltman; Jürgen Groet; Finbarr E Cotter; Dean Nizetic
Journal:  Proteome Sci       Date:  2009-08-28       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.